Bortezomib use and outcomes for the treatment of multiple myeloma-Reference-Cited by-同舟云学术

Bortezomib use and outcomes for the treatment of multiple myeloma

Published:2020-09 Issue:9 Volume:50 Page:1059-1066
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Intern Med J

Author:

Loke Crystal¹^ORCID,Mollee Peter²,McPherson Ian²,Walpole Euan²,Yue Mimi²,Mutsando Howard³,Wong Phillip³,Weston Helen⁴,Tomlinson Ross⁴,Hollingworth Samantha¹^ORCID

Affiliation:

1. School of Pharmacy The University of Queensland Brisbane Queensland Australia

2. Department of Cancer Services Princess Alexandra Hospital Brisbane Queensland Australia

3. Toowoomba Hospital Darling Downs Hospital and Health Services Toowoomba Queensland Australia

4. Regional Cancer Care, Cancer Care Services Sunshine Coast University Hospital Sunshine Coast Queensland Australia

Publisher

Wiley

Subject

Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.14886

Reference52 articles.

1. Multiple Myeloma

2. Emerging therapies for multiple myeloma

3. Bortezomib in newly diagnosed multiple myeloma

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma;Dermatopathology;2023-07-21

2. Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review;Diagnostics;2023-07-10

3. Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis;EUR RESPIR J;2022

4. Treatment Outcomes with Reduced-Dose Bortezomib in Adult Patients with Multiple Myeloma: A Single-Center Experience;Asian Journal of Oncology;2022-07-14

5. Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis;European Respiratory Journal;2022-07-07